Another phase I trial is currently investigating the use of the MEK inhibitor binimetinib in combination with HCQ in KRAS-mutated pancreatic cancer patients with at least one prior treatment line for metastatic disease (NCT04132505). Here, KRAS is linked to familial pancreatic carcinoma.